ABSTRACT
INTRODUCTION Epitope-based cancer vaccination, comprised of minimal immunogenic portions of a cancer antigen, represents an immunotherapy that combines target specifi city with long-lasting immunity. Advances in epitope identifi cation and immunogenicity assays, as well as peptide formulation and delivery methods, have bolstered interest in this approach. Increased understanding of the mechanisms of T cell-induced activation and immune tolerance has infl uenced the design of T cell-epitope vaccines. This chapter discusses the use of T cell-epitope vaccines for cancer.
